RxSight, a commercial-stage provider of an intraocular lens that can be adjusted after cataract surgery, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
RxSight markets its RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens and the RxSight Light Delivery Device, to offers the first and only commercially available intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
The Aliso Viejo, CA-based company was founded in 1997 and booked $15 million in sales for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol RXST. J.P. Morgan, BofA Securities, SVB Leerink, Wells Fargo Securities, and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.
